Taurolidine-citrate vs heparin as catheter lock solutions in paediatric patients
| ISRCTN | ISRCTN86885538 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN86885538 |
| Secondary identifying numbers | EA2/084/06 |
- Submission date
- 07/12/2006
- Registration date
- 16/01/2007
- Last edited
- 08/02/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Uwe Querfeld
Scientific
Scientific
Department of Pediatric Nephrology
Charité Universitätsmedizin Berlin
Berlin
13353
Germany
Study information
| Study design | Randomized prospective study in pediatric hospital with stratification for patients treated in renal/oncology/hematology departments |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Not specified |
| Study type | Not Specified |
| Scientific title | |
| Study acronym | Taurolock study |
| Study objectives | Use of taurolidine-citrate for catheter locking leads to a significant reduction of bacterial growth and catheter-related infections in paediatric patients with implanted central venous catheters |
| Ethics approval(s) | Approval received by local ethics committee (Ethikkommission 2 am Campus Virchow Klinikum) on 29 September 2006 (ref: EA2/084/06). |
| Health condition(s) or problem(s) studied | Catheter-related infections |
| Intervention | Taurolidine-citrate vs heparin as catheter lock solutions |
| Intervention type | Other |
| Primary outcome measure | Bacterial growth/biofilm formation in removed catheters |
| Secondary outcome measures | Catheter-related infections, catheter occlusions |
| Overall study start date | 01/01/2007 |
| Completion date | 31/12/2007 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Sex | Not Specified |
| Target number of participants | 100 |
| Key inclusion criteria | Paediatric patients with newly implanted central venous catheters |
| Key exclusion criteria | Bacteremia/sepsis ongoing; allergy against heparin or taurolidine |
| Date of first enrolment | 01/01/2007 |
| Date of final enrolment | 31/12/2007 |
Locations
Countries of recruitment
- Germany
Study participating centre
Department of Pediatric Nephrology
Berlin
13353
Germany
13353
Germany
Sponsor information
Tauropharm (Germany)
Industry
Industry
Jägerstraße 5a
97297
Waldbüttelbrunn
97297
Germany
Funders
Funder type
Industry
Tauropharm GmbH (Germany)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
